The Effect of Soluble Epoxide Hydrolase (SEH) on Depression

Nanfang Hospital, Southern Medical University

Status: Completed

Conditions: Major Depressive Disorder

Study type: Observational

Funder types: Other

Identifiers

NCT05575713

NFEC-2022-092

Details and patient eligibility

About

Depression is the most common mental disease and the second leading cause of chronic disease burden, which is closely related to suicidal behavior. The diagnosis and treatment of depression still lack of effective biological indicators, and about 30% of patients with depression still can not relieve their depressive symptoms after treatment. Previous studies have found that ATP release from astrocytes plays an important role in the occurrence, development and treatment of depression. Epoxy eicosotrienes (eets) are closely related to the function of the nervous system and may be the pathophysiological mechanism of depression. Soluble epoxide hydrolase (SEH) can regulate ATP release by affecting EET degradation, leading to depression like behavior and antidepressant effect, and sEH is closely related to cognitive function of depression.

Full description

This study is an observational study without any intervention treatment for the subjects. All subjects need to sign the informed consent before screening, and the successful subjects can enter the study. Routine clinical diagnosis and treatment were performed on patients with depression, and the treatment effect of depressive symptoms, neurocognitive function and suicide improvement were evaluated at the 2nd week, 1st, 2nd, 3rd, 6th and 12th months after enrollment, and statistical analysis was conducted. The treatment lasted until the subjects completed the 12th month follow-up or reached any of the withdrawal criteria. This study will clarify the relationship between sEH gene polymorphism and mRNA expression and depression and suicide behavior, and explore the predictive role of soluble epoxide hydrolase sEH in the treatment effect of depression, cognition and suicide improvement during the follow-up study.

Enrollment: 330 patients

Sex: All

Ages: 18 to 65 years old

Volunteers: Accepts Healthy Volunteers

Inclusion and exclusion criteria

• Inclusion criteria:

  1. Voluntarily sign informed consent;
  2. Age: 18-65 years old;
  3. Elementary school or above, able to understand and complete all inspections and assessments;
  4. Did not take any psychotropic drugs (including benzodiazepines) within 2 weeks before enrollment;
  5. After routine medical diagnosis by clinicians, they were divided into depression and healthy people.

• Exclusion criteria:

  1. Severe somatic or neurological diseases;
  2. Mental retardation and dementia;
  3. During pregnancy or breastfeeding;
  4. Heavy smoking, alcoholism and other substance abuse or dependence (within 3 months before enrollment);
  5. Electric shock treatment (within 3 months before enrollment);
  6. According to the judgment of the investigator, it is not suitable to participate in this study.

Trial design

330 participants in 2 patient groups

Major depressive disorder

Description:

Patients diagnosed with severe depressive episode according to the diagnostic and Statistical Manual of mental disorders, 5th Edition (DSM-V);

healthy volunteer

Description:

Person who did not meet the DSM-V diagnosis of any mental disease, had no family history of psychiatric disease, and had no history of suicidal behavior.